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Abstract
Sarcopenia, or loss of skeletal muscle mass and quality, has been studied as part of aging and adverse health
outcomes in elderly patients but has only recently been evaluated as a separate condition in cancer patients and
important indicator of adverse outcomes. Currently, its definition and method of assessment are still being debated.
Sarcopenia within an increasingly obese population has led to a subgroup with sarcopenic obesity, at even higher
risk of adverse outcomes. Yet, sarcopenia often goes undiagnosed in these patients, hidden beneath higher body
mass index. Identifying sarcopenic and sarcopenic obese subpopulations would allow for more effective treatment
plans and potential avoidance of suboptimal outcomes, as well as the chance to intervene and combat these
modifiable risk factors. This review will examine available literature on the definition and methods of evaluating
sarcopenia and sarcopenic obesity, summarize the effectiveness of sarcopenia and sarcopenic obesity as predictors of
outcomes after gastrointestinal cancer surgery, including colorectal cancer resection, liver resection, and pancreatic
resection, and outline strategies to minimize the impact of sarcopenia. It is clear that untreated sarcopenia and
sarcopenic obesity can be associated with suboptimal post-operative outcomes, especially infections and disease-free
or overall survival.
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Background
Sarcopenia, the loss of skeletal muscle mass and quality
that occurs as part of natural aging, can be exacerbated
by systemic illnesses. Within the last 10 years, this geri-
atric syndrome has received increasing attention as a
possible predictor of adverse outcomes after surgery
(Lentine et al. 2011; Mueller et al. 2015). Traditional
oncological therapies and perioperative nutritional as-
sessments that focus on weight loss and markers such as
serum albumin have overlooked sarcopenia as a deter-
minant of prognosis after oncological surgery. Presently,
there is no practical, objective, or easily accessible meas-
ure of individual frailty, a general concept that encom-
passes age-related decline across physiologic systems as
well as in psychological and social well-being, resulting
in impaired homeostatic reserve (Clegg et al. 2013;
Bauer and Sieber 2008; Singh et al. 2014). Sarcopenia,
considered a more reproducible signal of frailty, often
precedes its development and could more effectively
identify patients at higher risk of suboptimal benefit
from systemic chemotherapy and surgery (Peng et al.
2011; van Vledder et al. 2012; Buettner et al. 2016).
With the increased prevalence of obesity, those with
both sarcopenia and obesity (sarcopenic obesity (SO))
are at higher risk of adverse outcomes, including disability
(Baumgartner et al. 2004) and mortality (Batsis et al.
2014a). These associations have not been well investigated
in relation to many cancer surgeries. Sarcopenia is often
underdiagnosed (Fielding et al. 2011; Prado et al. 2008), as
it is not always easily characterized from overall weight
loss alone or decreased body mass index (BMI), especially
in obese patients (Batsis et al. 2014b). Establishing stand-
ard criteria is critical to accurately evaluate and make use
of its prognostic abilities.
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In this review, we aim to summarize recent literature
regarding the impact and effectiveness of sarcopenia and
SO as predictors of gastrointestinal (GI) oncologic sur-
gery outcomes, including colorectal cancer resection,
liver resection, and pancreatic resection, and promising
methods by which these risk factors can be modified.
Defining sarcopenia, cancer cachexia, and SO
Early definitions of sarcopenia rely upon measures of
muscle mass and neglect a functional specification. Evi-
dence suggests the relationship between low muscle mass
and adverse outcomes is not linear or direct; rather, they
are linked when low muscle mass is associated with
muscle weakness (Cruz-Jentoft et al. 2010; Studenski et al.
2014). Recent definitions have evolved to additionally
include measures of muscle performance or strength
(Table 1).
In 2010, the European Working Group on Sarcopenia
in Older People established a working clinical definition
of sarcopenia as the presence of both abnormally low
muscle mass and low muscle function, either physical
performance or strength, in the form of low gait speed
or low handgrip strength (Cruz-Jentoft et al. 2010).
In 2014, the Foundation for the National Institutes of
Health alternatively defined sarcopenia as a “differential
diagnosis” reached through sequential screening for poor
physical function, muscle weakness, and low muscle
mass. Low gait speed manifested poor physical perform-
ance, and inability to rise from a chair (without using
arms) or time required to complete five chair stands
were also useful standards. Muscle strength was assessed
through unadjusted grip strength and muscle mass via
body mass-adjusted appendicular lean mass (Studenski
et al. 2014).
Sarcopenia is further distinguished from general
cancer-related cachexia, “a multifactorial syndrome char-
acterized by an ongoing loss of skeletal muscle mass
(with or without loss of fat mass) that cannot be fully re-
versed by conventional nutritional support and leads to
progressive functional impairment,” which encompasses
varying levels of body fat and muscle loss (Dodson et al.
2011; Fearon et al. 2006; Fearon et al. 2011; Fouladiun et
al. 2005). Sarcopenia specifically denotes muscle loss
(Peng et al. 2012). While cancer cachexic patients ex-
perience weight loss and diminished BMI, sarcopenic pa-
tients can have normal or increased BMI. As a result, it
is still important to screen cancer surgery patients for
sarcopenia (Fearon et al. 2011).
During aging and malignancy, lean body mass is lost
while fat mass remains constant or increases, possibly
leading to SO. SO is defined by subjects who fulfill the
combination of criteria for sarcopenia and a given meas-
ure of adiposity, such as BMI, waist circumference
(WC), computerized tomography (CT)-derived total
body fat (TBF), or dual x-ray energy absorptiometry
(DXA)/bioelectric impedance analysis (BIA)-derived
body fat (Batsis et al. 2013; Lieffers et al. 2012) (Table 1).
Metrics of adiposity more precise than BMI, which fluc-
tuates with changes in both muscle and adiposity, may
predict cancer outcomes more accurately. Traditional
BMI cutoffs have poor diagnostic accuracy when identi-
fying obesity, especially in older populations (Batsis et al.
2016; Romero-Corral et al. 2008).
Previously, decreases in muscle mass were considered
largely responsible for muscle weakness and mobility im-
pairment in patients with SO, but current research sug-
gests that deterioration of muscle quality (evidenced by
phenomena such as “marbling” or fat infiltration into
muscle) is an overlooked contributor (Cruz-Jentoft et al.
2010). Both aging and obesity are associated with decline
in muscle quality and higher rates of fat infiltration
(Zamboni et al. 2008). Studies find that although obese
elderly subjects often acquire a higher absolute muscle
mass than non-obese frail and normal counterparts to
compensate for body habitus (Visser et al. 2002), they
have the poorest muscle quality and strength and, like
the non-obese frail, exhibit reduced functional status,
aerobic capacity, strength, balance, and gait speed
(Villareal et al. 2004). This suggests that sarcopenia
and SO may be seriously underdiagnosed, since previ-
ous definitions largely ignore muscle quality and the
retrospective nature of many existing studies investi-
gating sarcopenia and cancer surgery limits them to
criteria relying on muscle mass. Moreover, there re-
mains variability within cutoffs used across studies
and uncertainty regarding the applicability of these
criteria to all ethnic groups (Studenski et al. 2014).
Diagnosing sarcopenia and SO
Various morphometric measures are used to quantify
muscle mass (Table 1), including appendicular skeletal
muscle (ASM) index (the sum of lean soft-tissue masses for
the arms and legs adjusted by height) (Fig. 1) (Baumgartner
et al. 1998) and those of core muscles such as total skeletal
muscle cross-sectional area at the level of the third lumbar
vertebrae (L3mi) (Prado et al. 2008), total psoas area
(TPA) (Peng et al. 2011), and psoas density (PD)
(Sabel et al. 2011).
Muscle mass has traditionally been measured using
BIA or DXA (Chien et al. 2008), but presently, CT and
magnetic resonance imaging (MRI) are considered the
gold standard methods of assessing body composition in
research (Cruz-Jentoft et al. 2010; Bonekamp et al. 2008;
Malafarina et al. 2012). CT and MRI are not routinely
used in clinical practice for sarcopenia assessment or
adiposity assessment, due to concerns about radiation
and high cost (Cruz-Jentoft et al. 2010). DXA is inexpen-
sive, most precise for measuring appendicular muscle
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Table 1 Definitions and cutoffs for sarcopenia and sarcopenic obesity assessment
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fat infiltration
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Table 1 Definitions and cutoffs for sarcopenia and sarcopenic obesity assessment (Continued)
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HUAC A measure of muscle




To determine ASM, the sum of lean soft-tissue masses for the arms and legs is computed from CT scans and adjusted by height. To determine L3mi, two consecutive CT images are taken from the L3 to the iliac crest,
and cross-sectional areas of the sum of all the muscles in these regions are computed and adjusted by body surface area. To determine PD, CT scans of the left and right psoas muscles at the level of the fourth lumbar
vertebrae are used. To determine TPA, measure the cross-sectional area of the right and left psoas muscles from CT images at the level of L3 where both vertebral spinae are clearly visible. To determine TPV, take three
manual measurements at the level of L3 on the first slice where both iliac crests were visible to assess a total of 55 cm total psoas length and normalize for height. To determine HUAC, compute (right Hounsfield unit
calculation + left Hounsfield unit calculation)/2, where the right Hounsfield unit calculation = (right Hounsfield unit*right psoas area)/(total psoas area) and left Hounsfield unit calculation = (left Hounsfield unit*left psoas
area)/(total psoas area) from evaluation of both the right and left psoas at the L3 level
ASM appendicular skeletal muscle, SD standard deviation, L3mi L3 skeletal muscle index, or total skeletal muscle cross-sectional area at the level of the third lumbar vertebrae normalized for stature, Intra-abdominal fat
total cross-sectional area of visceral adipose tissue, TPA total psoas muscle area, measured at the level of the L3, TPV total psoas volume, measured at the level of the L3, HUAC Hounsfield unit average calculation,
measure of radiation attenuation or muscle density and fatty infiltration, measured at the level of the L3, PD psoas density or muscle attenuation (average radiodensity), measured at the cross-sectional areas of the left
and right psoas muscles at the level of the L4, VF visceral fat, visceral anterior-to-posterior distance, or the average distance between the anterior aspect of the vertebra and the linea alba, SFD subcutaneous fat distance, or











mass, and exposes patients to minimal radiation but is
not portable nor widely available for sarcopenia assessment
or adiposity assessment (Bauer and Sieber 2008; Cruz-
Jentoft et al. 2010). BIA is an inexpensive, readily reprodu-
cible, portable alternative, but results are easily confounded
by a number of factors, especially fluid status, and is not
preferred for adiposity assessment (Bauer and Sieber 2008).
New image analysis software packages can be used
with CT or MRI to streamline segmentation and obtain
more consistent body composition measures for sarco-
penia assessment. Semi-automated processes like SliceO-
matic, NIHImageJ, Analyze, and EasyVision have yielded
similar results in terms of reproducibility, while only
HippoFat, a fully automated program, has shown to be
slightly inferior (Bonekamp et al. 2008). While SliceO-
matic segments fastest, NIHImageJ and HippoFat are
free. Overall, these software packages have comparable
results in analyzing MRI (Bonekamp et al. 2008) and CT
images (Irving et al. 2007) but have yet to be incorpo-
rated into routine clinical practice.
Functional implications of SO
In patients >65, SO was associated with a two to three
times higher chance of reporting an instrumental activ-
ities of daily living (IADL) disability than lean sarcope-
nic, non-sarcopenic obese, or patients with normal body
composition (Baumgartner et al. 2004). While non-
sarcopenic obesity and SO were both associated with
lower physical activity than non-obese sarcopenic and
normal body types, only SO was significantly associated
with onset of IADL disability, and low physical activity
was not associated with IADL disability in the absence
of SO. Thus, SO is considered a worst-case scenario
compounding health risks of obesity and depleted lean
mass (i.e., malnutrition) (Villareal et al. 2004; Kyle et al.
2005; Roubenoff 2004; Davison et al. 2002), and cancer
patients with SO are at higher risk of oncologic
treatment-related toxicities and mortality (Tsai 2012).
Impact of sarcopenia and SO on patient outcome
Colorectal cancer resection
Sarcopenia has been shown to predict complications and
length of stay following colorectal surgery (Lieffers et al.
2012). Moreover, with rising levels of obesity in Western
society, sarcopenia may be “hidden beneath” higher
BMI.
A 2012 study of stage II–IV colorectal cancer patients
undergoing primary colorectal resection found that sar-
copenic patients had longer index hospitalization length
of stays and post-operative length of stay, especially in
those >65 (Table 2) (Lieffers et al. 2012). Sarcopenia was
associated with increased infection risk, especially in
those >65. Sarcopenic patients required more inpatient
rehabilitation, and co-morbidities including cardiac ar-
rhythmias, diabetes, hypertension, and deficiency anemia
were more common. In patients >65, sarcopenia inde-
pendently predicted post-operative infection and need
for rehabilitation facility care but did not predict these
or longer length of stay in younger patients. Though no
explanation was provided, this may be because younger
patients are healthier overall (more active, with fewer and
less severe conditions and better physiological reserve)
and exhibit smaller discrepancies in outcomes. The study
provides strong evidence for sarcopenia as a predictor of
short-term outcomes in colorectal cancer resection.
A 2015 retrospective study found significant associa-
tions between sarcopenia and long-term outcomes
(Miyamoto et al. 2015). Sarcopenia was independently
associated with higher disease recurrence, shorter
recurrence-free survival, and shorter overall survival.
Sarcopenia was also independently associated with
shorter cancer-specific survival.
Another retrospective study on colon cancer patients
undergoing colectomy obtained various morphometric
measures to compare their effectiveness as predictors of
post-operational outcomes to that of Charlson co-
morbidity index scores (Sabel et al. 2013). The single
Fig. 1 Comparison of sarcopenic and non-sarcopenic computed tomography images at the third lumbar vertebral level. A comparison of two
cirrhotic patients with identical BMI (32 kg/m2). Red color indicates skeletal muscle: rectus abdominis, oblique and lateral abdominal muscles,
psoas, and paraspinal muscles. The patient on the left is sarcopenic with L3mi of 49.82 cm2/m2; the patient on the right is not sarcopenic with
L3mi of 70.8 cm2/m2. In their study of 112 cirrhotic patients, Montano-Loza et al. used abdominal CT images taken at the third lumbar vertebrae
and cutoffs provided by Baumgartner et al. in 1998
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Table 2 Association between sarcopenia or sarcopenic obesity (SO) and oncological surgery outcomes
Study Cancer
type
Association with short-term oncological outcomes? Association with long-term oncological outcomes?





– Unclear, but associated with
poorer functional status than
in non-sarcopenic obese







Yes, independently predicted post-operative
infection risk, longer inpatient rehabilitation,
associated with higher risk of obstruction,
longer index hospitalization length of stay,




Colon Yes, independently predicted surgical
complications and infectious complications,
associated with infectious post-operative
complications





No, not an independent predictor of
disease-free or overall survival







– – Yes, independently associated with disease
recurrence rate, overall mortality, cancer-specific









– – Yes, independently predicted disease-free







Yes, independently predicted disproportionally
small total functional liver volume
Unclear, but fat-free body










Yes, independently predicted major post-
operative complications, associated with risk
of post-operative complications, overall
morbidity risk, longer hospital stays, extended
ICU stays
Yes, associated with major
post-operative complications,
longer hospital stays, extended
ICU stays
No, not associated with recurrence-free
survival, overall survival or risk of recurrence








No, not significantly associated with risk of
major post-operative complications, presence
of liver surgery-specific composite endpointa
(LSSCEP) items
No, not significantly associated
with risk of major post-operative
complications, occurrence of one
or more of the LSSCEP items
No, not significantly associated with initial
hospital length of stay, readmission rates,
median disease-free survival, or overall survival
Yes, not predictive of initial hospital
length of stay, disease-free survival,
or overall survival, but significantly




Liver Yes, independent predictor of liver
dysfunction






Liver No, not associated with severe post-operative
complication rate, post-operative mortality or
morbidity rates
– Yes, independently associated with overall
and disease-free survival
–
Liver Yes, associated with major post-operative
complication (Clavien-Dindo grade ≥IIIa) and
– Yes, associated with overall survival, but not
associated with disease-free survival




















Pancreatic No, not associated with overall morbidity,
major post-operative complications, length
of hospital stays, length of ICU stays, or hazard
of 90-day death




Pancreatic Yes, TPA-sarcopenia not associated with
morbidity, but TPV-sarcopenia associated with
post-operative complications, major
complications, and length of hospital stay.
TPV-sarcopenia also independently associated
with post-operative complications
Yes, TPV-SO associated with
post-operative complications
Yes, TPV-sarcopenia associated with risk of






Pancreatic Yes, HUAC independently predicted length of
stay, ICU stay, major grade III post-operative
complications, incidence of any complications.
TPA independently predicted length of stay
– No, HUAC did not predict post-operative
overall survival
–












best predictor of any surgical or infectious complications
was PD. When considering PD, Charlson scores, age or
BMI, or specific co-morbidities were not statistically
significant.
After final multivariate models controlled for age and
Charlson score, PD was not significantly associated with
disease-free or overall survival, but TBF was. The au-
thors concluded that PD-sarcopenia is mainly predictive
of non-colorectal cancer deaths in the population and
hypothesized that frailty, or immunologic correlates,
contributes less to the natural progression of colorectal
cancer than it may to other cancers, such as melanoma,
which an earlier study by the same authors suggested
(Sabel et al. 2011).
A separate cross-sectional study found that SO in pa-
tients with solid tumors of the respiratory tract, colon,
rectum, or other GI sites was significantly related to
worse functional status and independently predicted sur-
vival (Prado et al. 2008).
More research is needed to clarify the most effective
method of sarcopenia assessment in regard to colorectal
cancer resection outcomes. Sarcopenia’s effectiveness as
a predictor of long-term outcomes following colorectal
cancer resection is unclear, as well as the associations
between SO and short- and long-term outcomes.
Colorectal liver metastases and hepatectomy
Sarcopenia has also been investigated in relation to liver
resection. In 2012, a study on patients undergoing colo-
rectal cancer liver metastases determined that sarcopenia
was significantly associated with disproportionally small
total functional liver volume (TFLV) and impaired short-
term outcomes after surgery (Dello et al. 2013). Significant
correlation was also found between fat-free body mass
and TFLV.
In a separate retrospective analysis, sarcopenia pre-
dicted short-term outcomes, but not long-term ones
(Peng et al. 2011). Peng et al. found that sarcopenia was
strongly univariately associated with increased risk of
post-operative complications and overall morbidity, with
sarcopenic patients >3 times more likely to develop a
major (Clavien grade ≥3) complication (Clavien et al.
2009). Neither TPA nor sarcopenia was predictive of
recurrence-free survival, long-term overall survival, or
risk of recurrence. While sarcopenic patients had longer
hospital stays and higher chances of extended ICU stay
(>2 days), SO patients were at even higher risk of both.
In addition, SO was associated with an even greater risk
of Clavien grade ≥3 complications.
Patients with SO tended to have shorter median overall
survival than other patients but, like sarcopenic patients,
did not have significant differences in recurrence-free sur-
vival compared to the entire cohort. These observations
support conclusions from Sabel et al. that perhaps
sarcopenia has a less significant impact on the natural
progression of colorectal cancer than for other cancers
and thus predicts short-term outcomes following surgery
in colorectal cancer, but not long-term survival.
However, in another retrospective study, sarcopenic pa-
tients had shorter median disease-free survival and lower
1-, 3-, and 5-year disease-free survival rates compared to
non-sarcopenic patients (Fig. 2) (van Vledder et al. 2012).
They also had decreased median overall survival and di-
minished 1-, 3-, and 5-year overall survival rates. Ultim-
ately, sarcopenia independently predicted worse survival.
Most recently, however, a 2015 study found neither
sarcopenia nor SO to be associated with short-term out-
comes such as risk of major post-operative complications
or morbidity (Lodewick et al. 2015). Moreover, sarcopenia
was not significantly associated with long-term outcomes,
including readmission rates or disease-free or overall
survival. Interestingly, Lodewick et al. observed that
sarcopenic patients had significantly higher percentage
body fat and investigated SO in relation to outcomes.
SO predicted higher readmission rates but no other
long-term outcomes.
van Vledder et al.’s findings thus conflict with Peng et
al.’s that sarcopenia does not predict long-term survival
outcomes, and Lodewick et al. conflict with both on sarco-
penia’s association with short- and long-term outcomes.
While multiple studies have supported an association be-
tween sarcopenia and short-term outcomes following hep-
atectomy of colorectal liver metastases, uncertainty
remains about this association and surrounding sarcope-
nia’s relation to long-term outcomes.
Fig. 2 Example segmented L3 computed tomography image for
skeletal muscle assessment of patient undergoing hepatic resection.
L3mi computed tomogram shows highlighted areas of subcutaneous
(green) and intra-abdominal fat (yellow) and skeletal muscle mass (red).
van Vledder et al. found a variety of body compositions within their
population of 196 patients who underwent hepatic resection for
colorectal liver metastases
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Hepatocellular carcinoma and hepatectomy
A 2013 retrospective study on partial hepatectomy in pa-
tients with hepatocellular carcinoma (HCC) noted that
there is currently no objective, accessible, accurate meas-
ure of a patient’s condition before undergoing hepatec-
tomy (Harimoto et al. 2013). While the American
Society of Anesthesiologists’ (ASA) grading estimates
functional status, it is subjective (Makary et al. 2010).
Child-Pugh scores are not always reliable metrics of hep-
atic reserve, and Model for End-Stage Liver Disease
(MELD) scores quantify mortality risk in end-stage liver
disease and organ allocation processes (Teh et al. 2005).
In this study, sarcopenia independently predicted overall
and recurrence-free survival following surgery (Harimoto
et al. 2013). As serum albumin levels were significantly
lower and indocyanine green dye retention rate at 15 min
(ICGR15) values higher in sarcopenic patients than in
non-sarcopenic patients (conveying less effective hepatic
removal of synthetic dye from plasma, worse hepatic func-
tional reserve and ability to regenerate), sarcopenia was
significantly associated with liver dysfunction. This study
strongly supported sarcopenia as a predictor of short- and
long-term outcomes following hepatectomy.
Subsequent studies disagreed. A 2015 retrospective
study found that while sarcopenia was independently as-
sociated with overall and disease-free survival, it was not
with short-term outcomes (Voron et al. 2015). Post-
operative mortality, morbidity, and major complication
rates were higher in sarcopenic than non-sarcopenic
subjects but not statistically significantly so.
A separate 2015 retrospective study reaffirmed initial
findings from Harimoto et al. (Levolger et al. 2015). Un-
like Voron et al., Levolger et al. discovered that sarcope-
nia was associated with short-term outcomes such as
increased risk of major post-operative complications and
treatment-related mortality (death within 90 days of
treatment). It was also associated with some long-term
outcomes, like shorter overall survival, but not disease-
free survival.
Further research needs to evaluate the effectiveness of
sarcopenia as a predictor of short-term outcomes follow-
ing hepatectomy for hepatocellular carcinoma and clarify
the extent to which it is a useful predictor of long-term
outcomes.
Additionally, Voron et al. reported a wide range of
BMI across sarcopenic subjects and emphasized the lim-
ited practicality of BMI in sarcopenia determination
without CT analysis. Three subjects with identical BMI
had varying L3mi values and sarcopenic status. Similarly,
Levolger et al. noted the prevalence of sarcopenia in
various body compositions and found that those over-
weight or obese and sarcopenic have significantly shorter
median survival rates than non-sarcopenic obese or
overweight. These findings highlight the necessity of
using CT to separately screen for sarcopenia, which is
convenient, as many hepatocellular carcinoma patients
already undergo routine imaging (Voron et al. 2015).
Pancreatic adenocarcinoma and pancreatic resection
Recent literature has found that factors such as co-
morbidity, anemia, and sarcopenia may affect post-
operative outcome as significantly as adjuvant oncological
treatments (Fearon et al. 2013). Considerable variation in
30-day morbidity and mortality following cancer surgery
and in long-term outcomes between countries supports
the idea that factors outside traditional multidisciplinary
team consideration may be important determinants of
outcome (Baili et al. 2008; van Gijn et al. 2010).
A retrospective study on patients undergoing resection
of pancreatic adenocarcinoma found that sarcopenia was
an objective measure of patient frailty strongly predictive
of long-term outcomes, independent of tumor-specific
factors (Peng et al. 2012). Sarcopenia was not associated
with short-term outcomes such as risk of overall mor-
bidity or major complications, median ICU stays, or
length of hospital stays. It was associated with increased
risk of 3-year mortality. This relationship suggests that
perhaps individual patient characteristics have a stronger
impact on long-term outcomes of pancreatic resection
than tumor-specific factors do.
However, more recent retrospective studies using volu-
metric or density psoas metrics found stronger associations
between sarcopenia and short-term outcomes. In 2015, a
retrospective study revealed stronger associations between
total psoas volume (TPV)-sarcopenia and short-term out-
comes than with TPA-sarcopenia (Amini et al. 2015).
While TPA-sarcopenia was significantly related to risk of
morbidity, TPV-sarcopenia was significantly associated
with risk of any post-operative complication, risk of major
complications, and length of hospital stay. Moreover, TPV-
sarcopenia independently predicted risk of death. TPV-SO
was also associated with higher risk of post-operative com-
plications compared to non-sarcopenic obese.
The same year, Joglekar et al. investigated the Houns-
field unit average calculation (HUAC), a measure of psoas
muscle density and fatty infiltration, along with TPA
(Joglekar et al. 2015). Like TPV-sarcopenia, they found
that HUAC-sarcopenia was associated with more short-
term outcomes than TPA-sarcopenia. TPA-sarcopenia
was associated with longer length of hospital stay, while
HUAC-sarcopenia was associated with longer length of
hospital stay, length of ICU stay, risk of any post-operative
complication, and risk of major complications. One point
of contrast between Joglekar et al. and Amini et al. was
that unlike TPV-sarcopenia, HUAC-sarcopenia did not
strongly predict long-term outcomes.
These findings reiterate the importance of identifying
the most clinically significant assessment methods of
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sarcopenia before determining its utility as a predictor.
Amini et al. determined that volumetric standards for
sarcopenia like TPV might be more clinically useful as
predictors of cancer surgery outcomes than cross-sectional
area measures such as TPA. Similarly, a definition based
on muscle density forecasted short-term outcomes
better than TPA (though not long-term outcomes)
(Joglekar et al. 2015).
Strategies to minimize the impact of sarcopenia
and SO
While sarcopenia assessment can help identify cancer
surgery patients at risk of worse outcomes, it is important
to note that sarcopenia and SO themselves are modifiable.
The most effective interventions to date are physical exer-
cise and adequate nutritional protein intake (Deutz et al.
2014; Bauer et al. 2013). Pharmacological therapies for
sarcopenia including inhibitors of myostatin, testosterone,
selected androgen receptor modulators, ghrelin agonists,
and angiotensin-converting enzyme (ACE) inhibitors have
been evaluated, but preliminary trials have found that they
are less effective than postulated (Molfino et al. 2016;
Morley et al. 2014). In older adults vulnerable to func-
tional decline, moderate-intensity physical activity signifi-
cantly reduces risk of onset of major mobility disability
compared to health education and, to a larger degree, risk
of persistent mobility disability (Pahor et al. 2014). Since
the primary outcome of sarcopenia is mobility disability, a
proven intervention from the mobility disability literature,
moderate physical activity, is a promising intervention for
non-aging sarcopenic patients as well. In addition, relative
sarcopenia in obese elderly was significantly ameliorated
by diet regimens, exercise programs, or their combination
(Villareal et al. 2011). Fat mass decreased under diet or ex-
ercise programs or their combination, but lean body mass
decreased less under diet-exercise than with only diet and
increased under an exercise program. A diet and exercise
program yielded the greatest improvements in physical
performance and the most consistent changes in strength,
balance, and gait and thus may be an important therapy
for SO subpopulations.
Conclusions
The impact of sarcopenia on post-operative oncologic
outcomes and its usefulness as a predictor is still unclear
and often conflicting, particularly in the case of hepatec-
tomy for colorectal liver metastases and hepatectomy for
hepatocellular carcinoma. However, sarcopenia is prom-
ising as a predictor of short-term outcomes following
colorectal cancer surgery and long-term outcomes fol-
lowing hepatectomy for hepatocellular carcinoma. SO is
promising as a predictor of long-term outcomes follow-
ing hepatectomy for hepatocellular carcinoma and short-
term outcomes following pancreatic resection. The other
associations need additional clarification, as studies pro-
vided inconsistent results.
There remains considerable variation in definition,
cutoffs, and assessment methods for sarcopenia and SO,
which makes translation to clinical practice complicated.
Recent criteria incorporating both grip strength and ap-
pendicular skeletal muscle allow more clinically mean-
ingful associations with long-term outcomes and are
preferred to definitions excluding a functional compo-
nent (Studenski et al. 2014; McLean et al. 2014). Though
ramifications have been explored in geriatric populations,
sarcopenia assessment may be more easily assimilated into
clinical practice for cancer surgery patients, as routine im-
aging is already completed for these populations. Semi-
automated segmentation software also promises to play a
major role in streamlining sarcopenia assessment integra-
tion into routine practice.
Sarcopenia and SO may predict short- and long-term
outcomes, and effective identification of patients at risk
of poorer outcomes from cancer surgery allows for tai-
lored interventions. As clinicians become increasingly
aware of this subtle form of malnutrition, addressing sar-
copenia preoperatively can optimize outcomes for at-risk
patients.
Future directions
Further research is needed to reach consensus regarding
the ideal manner of assessing sarcopenia in order to pre-
dict outcomes after various cancer surgeries and across
cancers in a broad clinical sense. The prevalence and im-
pact of SO in various cancer surgeries requires further
examination. Risk of mortality associated with SO for all
types of patients should be further evaluated (Prado et al.
2008; Batsis et al. 2013). It remains unclear whether the
added risk from SO is the sum of the individual impacts
of obesity and sarcopenia or whether these conditions fur-
ther interact with each other. Finally, current interven-
tions for sarcopenia and SO have not been robustly
verified, due to challenges from risk of adverse reactions
when dealing with sarcopenic populations (Cesari M
2016). Furthermore, these interventions have yet to be
tested specifically with regard to cancer surgery patients.
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